

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/195931 A3

(51) International Patent Classification:
C12Q 1/6886 (2018.01) G01N 33/574 (2006.01)

(21) International Application Number:
PCT/SG2023/050239

(22) International Filing Date:
06 April 2023 (06.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202203606T 07 April 2022 (07.04.2022) SG

(71) Applicants: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). NATIONAL UNIVERSITY HOSPITAL (SINGAPORE) PTE LTD [SG/SG]; 1E Kent Ridge Road, #13-00, Singapore 119228 (SG).

(72) Inventors: TAY, Kai Xun, Joshua; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Otolaryngology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LOH, Kwok Seng; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Otolaryngology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TEO, Wei Keat; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Otolaryngology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). LOH, Woei Shyang; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Otolaryngology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). SURYANI, Luvita; c/o National University of Singapore, Yong Loo Lin School of Medicine / Dept. of Otolaryngology, 21 Lower Kent Ridge Road, Singapore 119077 (SG). WU, Bingcheng; c/o National University Hospital (Singapore) Pte Ltd, Department of Pathology, 5 Lower Kent Ridge Road, #03-208A, Singapore 119074 (SG).

(74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay, #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:
30 November 2023 (30.11.2023)



WO 2023/195931 A3

(54) Title: METHOD FOR DETECTING HIGH-RISK NASOPHARYNGEAL CANCER

(57) Abstract: The invention relates generally to the field of oncology. Provided herein is a method for predicting the likelihood of recurrence or prognosis of a cancer in a subject, comprising comparing the level of expression of one or more biomarkers selected from the group consisting of Fibroblast Growth Factor 2 (FGF2), Complement Component 3 (C3), and GTPase, IMAF Family Member 7 (GIMAP7) in a sample obtained from the subject to a reference. In particular, the cancer is nasopharyngeal cancer. Also provided is a composition or solid support comprising a plurality of DNA/RNA complexes, wherein each DNA/mRNA complex in the plurality comprises a biomarker and a first and second DNA probe hybridized to the biomarker, wherein the plurality of DNA/mRNA complexes comprise one or more biomarkers selected from the group consisting of FGF2, C3, and GIMAP7.